

Immunotherapy in Oncology: Current Status, Future Potential

Thursday, 16 April 2015
18:20 – 19:20

ELCC 2015 Industry
Satellite Symposium
Sponsored by MSD

Palexpo Exhibition and Congress Center
Room C
Geneva, Switzerland

Chair: Rolf Stahel (Switzerland)

FACULTY

Rolf Stahel

Professor of Oncology
Department of Oncology
University Hospital
Zurich, Switzerland

Erik Thunnissen

Consultant Pathologist and Staff
Member
Department of Pathology
VU University Medical Centre
(VUmc)
Amsterdam, The Netherlands

Joseph Paul Eder Jr.

Professor of Medicine
Assistant Director, Experimental
Therapeutics
Director, Phase I Program
Yale University School of Medicine
– Yale Cancer Center
New Haven, Connecticut, USA

EDUCATIONAL OBJECTIVES:

Interactive session based on case studies:

- Educate on the PD-1 class of immunotherapy as an anti-cancer strategy
- Educate on potential clinical biomarkers and their role in guiding immunotherapy in oncology
- Establish better understanding of the practical implications of targeting the immune system through PD-1 blockade in patients with cancer

AGENDA

18:20 – 18:25	Introduction and Opening Remarks	Rolf Stahel
18:25 – 18:50	Case Study #1	
18:50 – 19:15	Case Study #2	
19:15 – 19:20	Closing Remarks	Rolf Stahel